True Wealth Design’s Definium Therapeutics DFTX Stock Holding History

True Wealth Design’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19	Closed	-$109	–	1462
2024 Q3	$109	Buy	+19	New	+$132	﹤0.01%	1222

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

True Wealth Design's DFTX Position: Q4 2024 in Review

True Wealth Design sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 19 shares — an estimated $109 sold.

True Wealth Design first reported a position in DFTX in Q3 2024 and held it in 1 quarter. The position peaked at $109 in Q3 2024. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

True Wealth Design reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
True Wealth Design sold 19 Definium Therapeutics shares in Q4 2024, an estimated $109.
True Wealth Design first reported a position in Definium Therapeutics in Q3 2024 and held it in 1 quarter.
True Wealth Design's Definium Therapeutics position peaked at $109 in Q3 2024.
172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on True Wealth Design's 13F filing for Q4 2024, filed 14 Feb 2025.